Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Andreas Seeber"'
Autor:
Wei Zhong, Xiaoxing Gao, Jing Zhao, Xiaoyan Liu, Mariano Provencio, Xiangning Liu, Qing Zhou, Yuequan Shi, Yuan Yue, Yan Xu, Florian Kocher, Terence M. Williams, Mengzhao Wang, Jia Liu, Dongming Zhang, Andreas Seeber, Minjiang Chen, Jacek Jassem
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: Peripheral blood-based biomarkers (PBB) predicting response, survival and immune-related adverse events (irAEs) in patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are still a matt
Autor:
Georg Pall, Gerlig Widmann, Dominik Wolf, Andreas Seeber, Andreas Pircher, Herbert Maier, Katja Schmitz, Laurenz Nagl
Publikováno v:
memo - Magazine of European Medical Oncology. 14:392-396
SummaryPrimary pulmonary sarcomas (PPS) are rare mesenchymal lung cancers, which do not present clinically or radiological different to lung carcinomas. Definite PPS diagnosis can only be made by histological analysis and detailed staging examination
Autor:
Xiaojian Zhang, Yongjie Yang, Jingli Lu, Yanfang Ma, Cesare Gridelli, Florian Kocher, Mariano Provencio, Qiwen Zhang, Jian Kang, Nobuhiko Seki, Chen Xi, Kefeng Liu, Andreas Seeber, Shuzhang Du, Xuedong Jia, Yusuke Tomita
Publikováno v:
Transl Lung Cancer Res
Background In recent years, the number of clinical practice guidelines (CPGs) for lung cancer has increased, but the quality of these guidelines has not been systematically assessed so far. Our aim was to assess the reporting quality of CPGs on lung
Autor:
Andreas Seeber, Richard Greil, Joanna Szkandera, Thomas Jäger, Florian Kocher, Franz Romeder, Lukas Weiss, Thomas Brodowicz, Susanne Kostner, Thomas Kühr, Petra Pichler
Publikováno v:
Wiener klinische Wochenschrift. 133:21-25
e22550 Background: Olaratumab is a humanized monoclonal anti platelet-derived growth factor receptor α antibody that has been approved in combination with doxorubicin for the treatment of patients with metastatic soft tissue sarcoma (STS). The purpo
Autor:
Gilbert Spizzo, Andreas Seeber, Robert C. F. Leonard, Guenther Gastl, Uwe Siebert, Klaus Schuster, Andreas Voss
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 17, Iss 1, Pp 1-5 (2019)
Cost Effectiveness and Resource Allocation : C/E
Cost Effectiveness and Resource Allocation : C/E
Background Tumor profiling is increasingly used in advanced cancer patients to define treatment options, especially in refractory cases where no standard treatment is available. Caris Molecular Intelligence (CMI) is a multiplatform tumor profiling se
Autor:
Francesca Battaglin, W. Michael Korn, Mohamed E. Salem, Philip A. Philip, Moh’d Khushman, Axel Grothey, Davide Soldato, Wafik S. El-Deiry, Sukeshi Patel Arora, Wu Zhang, Richard M. Goldberg, Joanne Xiu, John L. Marshall, Heinz-Josef Lenz, Martin D. Berger, Madiha Naseem, Alberto Puccini, Ryuma Tokunaga, Anthony F. Shields, Andreas Seeber, Michael J. Hall
Publikováno v:
Puccini, Alberto; Seeber, Andreas; Xiu, Joanne; Goldberg, Richard M; Soldato, Davide; Grothey, Axel; Shields, Anthony F; Salem, Mohamed E; Battaglin, Francesca; Berger, Martin Dave; El-Deiry, Wafik S; Tokunaga, Ryuma; Naseem, Madiha; Zhang, Wu; Arora, Sukeshi Patel; Khushman, Moh'd M; Hall, Michael J; Philip, Philip A; Marshall, John L; Korn, W Michael; ... (2021). Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. NPJ precision oncology, 5(1), p. 95. Springer Nature 10.1038/s41698-021-00230-y
NPJ Precision Oncology
npj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
NPJ Precision Oncology
npj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
Lymph nodes (LNs) and distant metastases can arise from independent subclones of the primary tumor. Herein, we characterized the molecular landscape and the differences between LNs, distant metastases and primary colorectal cancers (CRCs). Samples we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eef01f3b44d477510a8039ec853eee53
https://boris.unibe.ch/160885/1/41698_2021_Article_230.pdf
https://boris.unibe.ch/160885/1/41698_2021_Article_230.pdf
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Mutated germline alleles in the DNA damage repair (DDR) genes “breast cancer gene 1” (BRCA1) andBRCA2have originally been identified as major susceptibility genes in breast and ovarian cancers. With the establishment and approval of more cost-eff
Autor:
Janick Selves, Sébastien Humbert, Peggy Dartigues, Manuela Delage-Corre, Chrystalla Prokopiou, Liana Veresezan, Jean Donadieu, Séverine Valmary-Degano, Patrick Tas, Olivier Lucidarme, Frédéric Charlotte, Andreas Seeber, Alexandre Malakhia, Julien Haroche, Zofia Hélias-Rodzewicz, Jerome Razanamahery, Fleur Cohen-Aubart, Merja Kunnamo, Abdellatif Tazi, Irena Ungureanu, Dominique Cazals-Hatem, Jean-François Emile
Publikováno v:
BMJ Open Gastroenterology
BMJ Open Gastroenterology, Vol 8, Iss 1 (2021)
BMJ Open Gastroenterology, BMJ Publishing Group, 2021, 8 (1), pp.e000622. ⟨10.1136/bmjgast-2021-000622⟩
BMJ Open Gastroenterology, Vol 8, Iss 1 (2021)
BMJ Open Gastroenterology, BMJ Publishing Group, 2021, 8 (1), pp.e000622. ⟨10.1136/bmjgast-2021-000622⟩
ObjectivePeritoneal or mesenteric tumours may correspond to several tumour types or tumour-like conditions, some of them being represented by histiocytosis. This rare condition often poses diagnostic difficulties that can lead to important time delay
Autor:
Renate Schaberl-Moser, Jakob M. Riedl, Konstantin Schlick, Arno Amann, Philipp J Jost, Richard Greil, Martin Pichler, Armin Gerger, Dominik A. Barth, Moritz Müller, Dominik Kiem, Florian Posch, Andreas Seeber, Lena Horvath, Michael Stotz
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: The level of evidence for palliative second-line therapy in advanced esophageal squamous cell carcinoma (aESCC) is limited. This is the first study that reports efficacy data comparing second-line therapy + active symptom control (ASC) ve
Autor:
Diego Kauffmann-Guerrero, Arno Amann, Piotr Tymoszuk, Stefan Salcher, Florian Kocher, Florian Huemer, Gabriel Rinnerthaler, Dominik Wolf, Johannes Haybaeck, Sophia Daum, Amanda Tufman, Andreas Pircher, Andreas Seeber, Susanne Sprung
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 159
Background The tumor-microenvironment (TME) represents an attractive therapeutic target in NSCLC and plays an important role for efficacy of cancer therapeutics. We hypothesized that upregulation of collagen synthesis might be associated with adverse